What the SELECT study on semaglutide actually showed

How SELECT was designed and why it mattered

Most weight-loss trials measure kilograms lost. SELECT asked a different question entirely: can semaglutide reduce the chance of a heart attack, stroke, or cardiovascular death in people who already have established heart disease?

The trial recruited adults aged 45 or older with a BMI of 27 or above and a prior cardiovascular event or diagnosis, but crucially excluded anyone with type 2 diabetes. That exclusion was deliberate, it separated the cardiovascular effect from any blood-sugar benefit. Participants were randomised to semaglutide 2.4mg weekly or placebo, on top of standard care, and followed for a median of about 40 months across sites in 41 countries.

The result: a 20% relative risk reduction in the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke. The absolute risk reduction was around 1.5 percentage points, 6.5% in the semaglutide group versus 8.0% in the placebo group. Statistical significance was met. NICE's appraisal of semaglutide (TA875) notes cardiovascular risk as part of the clinical context for weight management, and SELECT's data are shaping how regulators and clinicians think about this class of medicine more broadly.

What SELECT could not fully answer was why the benefit appeared. Weight loss played some role, but cardiovascular event rates started diverging between groups earlier than the weight curves did, pointing to possible anti-inflammatory or direct vascular effects. That conversation is still active in the research literature.

SELECT versus the STEP weight-loss trials, related but not the same

It is worth being precise about which study is which, because SELECT and the STEP programme are often cited together. The STEP 1 study enrolled adults with obesity or overweight plus at least one weight-related condition and measured body-weight reduction over 68 weeks, that is where the widely quoted average loss of around 15% at the 2.4mg dose comes from.

SELECT was not a weight-loss trial. Its participants had lower average BMIs than STEP 1, already had cardiovascular disease, and the primary endpoint was heart outcomes, not the scales. The overlap is that both used semaglutide 2.4mg weekly and both ran long enough to be credible.

Together, the two programmes give a more complete picture: semaglutide at the licensed weight-management dose reduces body weight meaningfully in people with obesity, and in people with overweight plus existing cardiovascular disease it also reduces the risk of serious cardiac events. A separate and complementary programme, the STRIDE study, looked at physical function, a different angle again.

If you are comparing the evidence base for semaglutide versus tirzepatide, a broader look at Wegovy's clinical programme sets SELECT and STEP side by side with the SURMOUNT data.

What SELECT means for semaglutide's UK licence and who it applies to

In the UK, semaglutide 2.4mg is marketed as Wegovy by Novo Nordisk. Following SELECT, the MHRA expanded Wegovy's licence to include the reduction of major cardiovascular event risk in eligible adults, specifically, adults with established cardiovascular disease and a BMI of 27 or above. This is a separate indication from weight management; not everyone prescribed Wegovy for weight loss will automatically qualify for the cardiovascular indication, and vice versa.

For weight management, Wegovy is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. NICE recommends it within specialist weight management services, for a maximum of two years, with multidisciplinary support. NHS access remains limited to specific pathways with waiting lists; finding a regulated private route to Wegovy is how most people access it today outside those services.

The cardiovascular SELECT data are also one reason clinicians take this medicine seriously rather than treating it as a cosmetic shortcut. The MHRA's 2026 approval of semaglutide for MASH, a form of fatty liver disease, is another signal that semaglutide's clinical profile extends well beyond weight on a scale. Whether any of those indications are relevant to your situation is something a prescriber works through with you, not something a checklist can decide.

Practical context if you are considering semaglutide for weight management

SELECT tells us a great deal about semaglutide at a population level. It does not tell any individual whether this medicine is right for them, that depends on their medical history, current medicines, and other factors a prescriber weighs up. The semaglutide overview page covers eligibility, the dosing schedule, and what to expect from treatment in more practical terms.

Side effects in SELECT were consistent with those seen in the STEP trials: predominantly gastrointestinal (nausea, diarrhoea, vomiting) most often reported in the early weeks of treatment or after a dose step. Serious events were uncommon. The medicine is taken once weekly by subcutaneous injection; most people keep their pen in the fridge door and build the injection into whatever routine already anchors that part of their week.

If you are based in or around the capital, Wegovy access in London follows the same regulated private route as the rest of the UK. For a broader look at all available weight-management options, the treatment overview is the right starting point before a consultation.

Our prescribers read every consultation personally, a clinician reviews your answers the same day and decides on suitability. If you are ready to explore whether semaglutide fits your situation, start your free consultation and we will take it from there.